Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.

DeBord KL, Anderson DM, Marketon MM, Overheim KA, DePaolo RW, Ciletti NA, Jabri B, Schneewind O.

Infect Immun. 2006 Aug;74(8):4910-4.

2.

Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.

Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel TL, Elli D, Ciletti NA, Schneewind O.

Infect Immun. 2008 Dec;76(12):5588-97. doi: 10.1128/IAI.00699-08. Epub 2008 Sep 15.

3.

Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge.

Branger CG, Sun W, Torres-Escobar A, Perry R, Roland KL, Fetherston J, Curtiss R 3rd.

Vaccine. 2010 Dec 16;29(2):274-82. doi: 10.1016/j.vaccine.2010.10.033. Epub 2010 Oct 24.

5.

Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.

Quenee LE, Ciletti NA, Elli D, Hermanas TM, Schneewind O.

Vaccine. 2011 Sep 2;29(38):6572-83. doi: 10.1016/j.vaccine.2011.06.119. Epub 2011 Jul 16.

6.
7.

Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.

Erova TE, Rosenzweig JA, Sha J, Suarez G, Sierra JC, Kirtley ML, van Lier CJ, Telepnev MV, Motin VL, Chopra AK.

Clin Vaccine Immunol. 2013 Feb;20(2):227-38. doi: 10.1128/CVI.00597-12. Epub 2012 Dec 12.

8.

Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague.

Do Y, Koh H, Park CG, Dudziak D, Seo P, Mehandru S, Choi JH, Cheong C, Park S, Perlin DS, Powell BS, Steinman RM.

Eur J Immunol. 2010 Oct;40(10):2791-6. doi: 10.1002/eji.201040511.

9.

Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.

Sabhnani L, Manocha M, Sridevi K, Shashikiran D, Rayanade R, Rao DN.

FEMS Immunol Med Microbiol. 2003 Oct 15;38(3):215-29.

10.

Yersinia pestis caf1 variants and the limits of plague vaccine protection.

Quenee LE, Cornelius CA, Ciletti NA, Elli D, Schneewind O.

Infect Immun. 2008 May;76(5):2025-36. doi: 10.1128/IAI.00105-08. Epub 2008 Mar 17.

11.

LcrV plague vaccine with altered immunomodulatory properties.

Overheim KA, Depaolo RW, Debord KL, Morrin EM, Anderson DM, Green NM, Brubaker RR, Jabri B, Schneewind O.

Infect Immun. 2005 Aug;73(8):5152-9.

12.

TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.

Lin JS, Park S, Adamovicz JJ, Hill J, Bliska JB, Cote CK, Perlin DS, Amemiya K, Smiley ST.

Vaccine. 2010 Dec 16;29(2):357-62. doi: 10.1016/j.vaccine.2010.08.099. Epub 2010 Sep 15.

13.

Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.

Sanapala S, Rahav H, Patel H, Sun W, Curtiss R.

Vaccine. 2016 May 5;34(21):2410-2416. doi: 10.1016/j.vaccine.2016.03.094. Epub 2016 Apr 6.

14.

Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.

Anderson GW Jr, Leary SE, Williamson ED, Titball RW, Welkos SL, Worsham PL, Friedlander AM.

Infect Immun. 1996 Nov;64(11):4580-5.

15.

Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.

Gupta G, Khan AA, Rao DN.

Scand J Immunol. 2010 Mar;71(3):186-98. doi: 10.1111/j.1365-3083.2009.02365.x.

16.

Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.

Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, Shafferman A, Flashner Y, Mamroud E.

Vaccine. 2008 Mar 20;26(13):1616-25. doi: 10.1016/j.vaccine.2008.01.033. Epub 2008 Feb 6.

PMID:
18304706
17.

N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection.

Hill J, Leary S, Smither S, Best A, Pettersson J, Forsberg A, Lingard B, Lipka A, Brown KA, Williamson ED, Titball RW.

Vaccine. 2009 Nov 23;27(50):7073-9. doi: 10.1016/j.vaccine.2009.09.061. Epub 2009 Sep 26.

PMID:
19786138
18.

Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.

Kumar D, Kirimanjeswara G, Metzger DW.

Clin Vaccine Immunol. 2011 Nov;18(11):1925-35. doi: 10.1128/CVI.05117-11. Epub 2011 Aug 31.

19.
20.

Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.

Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW.

Microb Pathog. 1997 Sep;23(3):167-79.

PMID:
9281474

Supplemental Content

Support Center